Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADAM9
REST API REST API
Homo sapiens
ADAM9 is differentially expressed in 333 experiments: 122 organism parts: liver, bone marrow, ... (120 more);, 212 disease states: normal, glioblastoma, ... (210 more);, 129 cell types 470 cell lines 50 compound treatments and 77 other conditions.
Synonyms Mltng, KIAA0021, MCMP, MDC9, CORD9
Orthologs Adam9 (Mus musculus)   ADAM9 (Gallus gallus)   Neu3 (Drosophila melanogaster)   O77635_BOVIN (Bos taurus)   adam9 (Danio rerio)   Adam9 (Rattus norvegicus)   mmd (Drosophila melanogaster)   adam9 (Xenopus laevis)   ADAM9 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to hydrogen peroxide, plasma membrane, protein binding, positive regulation of protein secretion, cytoplasm, metalloendopeptidase activity, extracellular space, metallopeptidase activity, peptidase activity, SH3 domain binding, membrane protein ectodomain proteolysis, metal ion binding, transforming growth factor beta receptor signaling pathway, extracellular region, integrin-mediated signaling pathway, activation of MAPKK activity, cell adhesion, cell adhesion mediated by integrin, cell-matrix adhesion, integrin binding, proteolysis, integral to membrane, cell surface, zinc ion binding, cell-cell adhesion mediated by integrin, monocyte activation, laminin binding, response to calcium ion, response to tumor necrosis factor, intrinsic to external side of plasma membrane, positive regulation of cell adhesion mediated by integrin, protein kinase C binding, keratinocyte differentiation, PMA-inducible membrane protein ectodomain proteolysis, positive regulation of membrane protein ectodomain proteolysis, positive regulation of keratinocyte migration, collagen binding, response to manganese ion, positive regulation of macrophage fusion, response to glucocorticoid stimulus
InterPro Term Peptidase_M12B_N, Blood-coag_inhib_Disintegrin, ADAM_Cys-rich, EGF_3, Peptidase_M12B
UniProt Accession Q13443, C9J6H5, C9JPM3, A0AVL1, B4DDM8, F8WC54
Gene-Disease Assocation CONE-ROD DYSTROPHY 9; CORD9
Search EB-eye ENSG00000168615
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
AGS
2
E-MTAB-37, E-GEOD-15460
MOLT4
2
E-MTAB-37, E-MTAB-62
WI38
2
E-MTAB-37, E-MTAB-62
464 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (65 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-19240, E-GEOD-96, E-GEOD-3998, E-GEOD-3920
1
2
E-TABM-145, E-TABM-130
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
cardiac myocyte
1
2
E-AFMX-5, E-MTAB-25, E-TABM-145
CD19+ B cell
1
E-MEXP-1600
CD34+CD38-/lowCD19+ cell
1
E-MEXP-1403
123 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (69 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MEXP-2034, E-MTAB-62, E-MEXP-1327, E-GEOD-96
colon carcinoma
3
E-GEOD-3726, E-MTAB-62, E-MTAB-37
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-MEXP-567
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
obesity
2
E-GEOD-2508, E-MTAB-62
206 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (29 experiments)

Factor Value U/D Experiments
none
2
7
E-GEOD-5824, E-GEOD-2803, E-GEOD-2649, E-GEOD-20719, E-MEXP-1958, ... (9 experiments)
eicosapentaenoic acid
1
E-MEXP-1389
Cxcl12
1
E-GEOD-7307
TNF
1
E-GEOD-15205
control - keratinocyte growth factor
1
E-GEOD-7216
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
44 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-GEOD-837, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4342

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Processing time: 0.449 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM